Treatment of Periorbicular Hyperchromia Comparing 10% Thioglycolic Acid Peeling Versus Pulsed Intense Light
Launched by HOSPITAL DE CLINICAS DE PORTO ALEGRE · Aug 2, 2017
Trial Information
Current as of May 19, 2025
Unknown status
Keywords
ClinConnect Summary
It is a blinded randomized clinical trial, with the sample size calculated of 29 subjects, already considering 10% of possible losses and refusals. For this number was considered 80% power and significance level of 5%.
Selected patients will be invited to participate and informed about the characteristics of the study. If they do, they must sign a free and informed consent form.
At the first visit, some demographic data will be collected, including sex, age, phototype, history of smoking and / or alcohol consumption, family history of periocular hyperpigmentation, personal or family histo...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with periocular hyperchromia diagnosed by clinical examination. The volunteers included must have a pigmentary component, which may or may not present the anatomical component, determined through physical examination with the aid of dermoscopy, to be performed at the inclusion study visit.
- Exclusion Criteria:
- • Pregnant patients, active collagenase patients, patients using photosensitizing substances and areas with bacterial or viral infections, patients with scars or tattoos at the evaluated site, patients undergoing any treatment modality for periocular hyperpigmentation in the last 3 months.
About Hospital De Clinicas De Porto Alegre
Hospital de Clínicas de Porto Alegre (HCPA) is a leading academic medical center in Brazil, renowned for its commitment to advancing healthcare through innovative clinical research. As a sponsor of clinical trials, HCPA leverages its extensive expertise in various medical disciplines to conduct rigorous studies aimed at improving patient outcomes and contributing to the global medical community. With a multidisciplinary team of skilled professionals and state-of-the-art facilities, HCPA fosters a collaborative environment that prioritizes ethical standards, patient safety, and scientific integrity in all its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Porto Alegre, Rio Grande Do Sul, Brazil
Patients applied
Trial Officials
Juliana C Boza, PhD
Principal Investigator
Hospital de Clínicas de Porto Alegre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials